Compared to conventional anticancer drugs, PD-L1 inhibitors ICIs were associated with increased mortality due to immune-related severe cutaneous adverse reactions (SCARs), with SJS 28.5% vs. 24.5% and TEN 55.3% vs. 46%. This evidence concerns the gene CD274 and toxic epidermal necrolysis.